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Abstract
Background
Vaccination against the oncogenic human papillomavirus (HPV) types 16 and 18 will reduce
the prevalence of these types, thereby also reducing cervical cancer risk in unvaccinated
women. This (measurable) herd effect will be limited at first, but is expected to increase over
time. At a certain herd immunity level, tailoring screening to vaccination status may no lon-
ger be worth the additional effort. Moreover, uniform screening may be the only viable
option. We therefore investigated at what level of herd immunity it is cost-effective to also
reduce screening intensity in unvaccinated women.
Methods
We used the MISCAN-Cervix model to determine the optimal screening strategy for a pre-
vaccination population and for vaccinated women (~80% decreased risk), assuming a will-
ingness-to-pay of €50,000 per quality-adjusted life year gained. We considered HPV test-
ing, cytology testing and co-testing and varied the start age of screening, the screening
interval and the number of lifetime screens. We then calculated the incremental cost-effec-
tiveness ratio (ICER) of screening unvaccinated women with the strategy optimized to the
pre-vaccination population as compared to with the strategy optimized to vaccinated
women, assuming different herd immunity levels.
Results
Primary HPV screening with cytology triage was the optimal strategy, with 8 lifetime screens
for the pre-vaccination population and 3 for vaccinated women. The ICER of screening
unvaccinated women 8 times instead of 3 was €28,085 in the absence of herd immunity. At
around 50% herd immunity, the ICER reached €50,000.
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Conclusion
From a herd immunity level of 50% onwards, screening intensity based on the pre-vaccina-
tion risk level becomes cost-ineffective for unvaccinated women. Reducing the screening
intensity of uniform screening may then be considered.
Introduction
Infection with the human papillomavirus (HPV) has been identified as a necessary cause for
cervical cancer [1]. Both the bivalent vaccine (targeting HPV-types 16/18), which is used in the
Netherlands, and the quadrivalent vaccine (targeting HPV-types 6/11/16/18) are effective in
preventing the two highly oncogenic types 16 and 18 [2, 3], that are found in roughly 80% of
invasive cervical cancers [4]. Recently, a nonavalent vaccine has been approved [5], targeting
seven oncogenic (and two non-oncogenic) HPV-types and thereby potentially preventing
almost 90% of cervical cancers worldwide [6].
In the Netherlands, a catch-up campaign targeted all 13- to 16-year-old girls in 2009. Since
2010, all 12-year-old girls are offered vaccination. The three-dose vaccination coverage has
steadily increased from 49% in the 1993 birth cohort to 61% in the 2000 birth cohort [7, 8]. In
these partly vaccinated cohorts, the prevalence of HPV-16/18 infections is lower than in the
pre-vaccination population. Therefore, unvaccinated women in those cohorts will be at lower
risk for developing cervical cancer. While this indirect protective effect of vaccination, so-called
herd immunity, will be limited at first, it is expected to increase over time [9]. It can be esti-
mated by the percentage reduction in HPV-16/18 prevalence among unvaccinated women
who were offered vaccination, as compared to totally unvaccinated cohorts. In the Netherlands,
primary HPV screening will be implemented in 2016. From then, it could be relatively easy to
monitor HPV-16/18 prevalence in unvaccinated women.
In many developed countries, vaccinated cohorts are approaching the start age of cervical
cancer screening. Especially in settings where both vaccinated and unvaccinated women are
well represented, it is unclear what screening strategy should be offered. In the youngest vacci-
nated cohorts (with limited herd immunity), vaccinated women are at much lower risk than
unvaccinated women and screening based on vaccination status is likely more cost-effective
than current uniform screening [10–13]. However, vaccinated women may not accept being
offered less screening, solely because they adhered to vaccination guidelines. Screening based
on vaccination status also requires the linkage of the screening invitational system with vacci-
nation registries, which may not be (fully) possible in all settings.
As long as the follow-up of HPV vaccinated women in trials and population-based settings
is not long enough to observe (statistical) differences in cervical cancer rates between vacci-
nated and unvaccinated cohorts, countries are reluctant to reduce the screening frequency. In
the U.S., the same screening protocol is recommended for both vaccinated and unvaccinated
women [14, 15]. European guidelines even state that HPV vaccines cannot replace or modify
current routine cervical cancer screening protocols [16].
What is merely realized, is that women at reduced risk (due to either vaccination or herd
immunity) could also be harmed by too intensive screening. These women will be offered more
screening tests than needed, which increases their probability of being referred to the gynecolo-
gist in the absence of clinically relevant lesions. Women with abnormal cytology or HPV posi-
tive test results commonly experience fear, self-blame, distress and anxiety about cervical
cancer, which reduces their quality of life [17, 18]. The ethical justification of continuing
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screening optimized to unvaccinated women instead of to those who adhered to vaccination
guidelines, is therefore questionable. Moreover, it is probably very inefficient and cost-ineffec-
tive to do so. To avoid this inefficiency, screening should be optimized to vaccinated women as
soon as unvaccinated women are substantially protected via herd immunity. We investigated
at what level of herd immunity this would be justified for unvaccinated women.
Materials and Methods
Using the MISCAN-Cervix model, we determined two optimal screening strategies: one for a
pre-vaccination cohort, and one for a vaccinated cohort. To determine the level of herd immu-
nity for which it would be cost-effective to replace the first strategy by the second, both strate-
gies were applied to an unvaccinated cohort, assuming different levels of herd immunity.
MISCAN-Cervix model
The MISCAN-Cervix model, which is described in more detail in the model profile (S1 Appen-
dix), was used to estimate costs and effects of different screening strategies [19]. In all of the
analyses presented here, we simulated a cohort of 1 million women. While none of these
women were assumed to be affected by vaccination when determining the optimal screening
strategy for the pre-vaccination population, all of them were assumed to be vaccinated when
determining the optimal screening strategy for vaccinated women. Both these optimal strate-
gies were then applied to unvaccinated women assuming various herd immunity levels.
A fraction of these women will acquire HPV-infections and/or develop cervical intraepithe-
lial neoplasia (CIN) lesions. If these precursors progress to cervical cancer, women may die
from the disease. If the population undergoes screening, the disease can be detected and treated
in an earlier stage. As a result, cervical cancer death may be prevented or postponed.
The population at risk for cervical cancer was simulated based on demographic and hyster-
ectomy data [20, 21]; mortality from other causes was estimated using the observed age-specific
mortality in the Netherlands in 2013 [20]. The age-specific incidence of HPV-infections that
progress to cervical cancer was calibrated to the age-specific incidence of cervical cancer, which
was obtained from the Netherlands Cancer Registry (NCR) [22]. The age-specific incidence of
pre-invasive lesions that do not progress to cervical cancer was calibrated so that the simulated
detection rates of CIN lesions fit the observed detection rates in the Netherlands. These
observed detection rates were obtained from the Dutch Network and National Database for
Pathology (PALGA) for the period 2000–2007 [23]. The incidence of high-risk HPV-infections
that do not progress to CIN was calibrated so that the simulated prevalence of all high-risk
HPV-infections fits the observed high-risk HPV prevalence [24, 25].
In the model, disease is subdivided into seven sequential stages: high-risk HPV-infection,
three pre-invasive stages (CIN grade I, II and III), and three invasive stages (International Fed-
eration of Gynecology and Obstetrics (FIGO) stages IA, IB and II+) [26]. Pre-invasive and
FIGO IA stages can be diagnosed by screening only, because no symptoms will develop,
whereas stages IB and II+ can also be clinically diagnosed. Because precursors are usually not
progressive [27]; in the model, most HPV-infections will clear without ever resulting in neopla-
sia, and lesions in pre-invasive stages can regress spontaneously. In the hypothetical situation
without competing other-cause mortality, undetected preclinical invasive neoplasia will always
progress to clinical cancer. CIN grades I and II can develop in the absence of a high-risk HPV-
infection; in that case the lesion will always regress. CIN grade III or worse can only develop if
a high-risk HPV-infection is present [28].
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Screening policies
We simulated four different screening policies: (A) primary HPV screening with reflex cytol-
ogy triage and cytology triage after six months (future Dutch screening program), (B) primary
cytology with reflex HPV triage, (C) combined primary HPV and cytology (i.e. co-testing) with
HPV triage after 12 months, and (D) primary cytology with cytology and HPV triage after six
months and cytology triage after 18 months (current Dutch screening program). Policies (A)
and (B) were already found to be cost-effective in case of no herd immunity [29]; policies (C)
and (D) are included because of their resemblance with current practice in the U.S. and in the
Netherlands, respectively.
Screening schedules
Screening schedules differed by start age, screening interval and number of screens in a life-
time. Possible start ages were 25, 30, 35, 40 and 45 years. The screening interval varied from 5
to 20 years and the number of lifetime screens ranged from 1 to 12. Because screening women
older than 80 years is not likely to be beneficial [30], all strategies ended at or before the age of
80. In this way, 312 screening schedules were created.
Assumptions for screening and treatment
As we aimed to optimized screening for women who adhere to screening guidelines, we
assumed full attendance in both primary screening and triage testing (S1 Table). The sensitivity
of cytology (the probability that the result is at least atypical squamous cells of undetermined
significance (ASCUS)) was assumed to be 40% for CIN grade I, 50% for CIN grade II and 75%
for CIN grade III or cancer [31]. In the model calibration, the sensitivity of detecting at least
high-grade squamous intraepithelial lesion (HSIL) was estimated to be 4% for CIN grade I,
18% for CIN grade II, 56% for CIN grade III and 60% for cervical cancer. The specificity of
cytology was estimated at 97.6%. Based on the observed difference in CIN grade III or cancer
detection rates between cytology and the HPV test, we assumed the sensitivity of the HPV test
to be 85% for a high-risk HPV-infection [32]. Although contamination and cross-reactivity
may cause HPV tests to produce positive results in the absence of high-risk HPV-infections,
we assumed the specificity for the presence of HPV to be 100% and modelled a possible lack in
specificity by including fast-clearing infections.
Detection of pre-invasive lesions and their associated management, including treatment if
necessary, were assumed to lead to a 100% cure rate. A woman can, however, acquire new
HPV-infections and develop CIN lesions after CIN treatment. For invasive cancer, we deter-
mined age-specific and stage-specific survival probabilities based on data from the NCR [33].
Since cancers detected by screening are found in an earlier stage than clinically diagnosed ones,
women have a higher chance of survival. Using the NCR data, we estimated that if an invasive
cancer is screen-detected, the probability to die from cervical cancer is reduced by 89.4%, 50%
and 20% for FIGO stages IA, IB and II+, respectively [33].
Assumptions for costs and utility losses
The estimated costs are based on a societal perspective, and are reported in 2013 euros (S2
Table). Screening costs include the costs for the invitational system and quality assurance, time
and travel costs of the woman being screened, costs of smear taking, costs of evaluating the
smear, costs of repeat tests after an inadequate test result, and costs of registration in PALGA.
Diagnosis costs for women referred for colposcopy, treatment costs for detected pre-invasive
lesions, treatment costs for invasive cervical cancer and costs of palliative care were derived
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from previous cost studies performed in the Netherlands [34]. A small (psychological) loss in
quality of life was assumed for attending screening (including waiting for the result) and for
being in triage (including attending follow-up screenings) [35]. Larger losses in quality of life
were assumed for being diagnosed and treated for CIN or cancer, and for having a terminal
stage of cervical cancer [36, 37]. Both costs and health effects were discounted with an annual
rate of 3%.
Assumptions for vaccination
We assumed the efficacy of the bivalent vaccine as observed in the PATRICIA trial42,43, which
is 25.3% for HPV-infections without cytological abnormalities [38], and 35.0%, 54.8% and
93.2% for CIN grade I, II and III respectively (Table 1) [2]. As vaccination trials have not
showed any waning in vaccine efficacy until now [39], the protection from vaccination was
assumed to be lifelong. Due to limited follow-up of the trials, a reduction in cervical cancer
incidence has not been observed yet. However, studies do give estimates of the type-specific
reduction in HPV prevalence [40, 41]. In combination with the HPV-type distribution
observed in cervical cancer cases in western Europe [4], the vaccine efficacy for cervical cancer
was estimated at 83.8%. In this calculation we assumed that all cervical cancers are caused by a
single oncogenic HPV-type, thereby avoiding overestimating the effect of the vaccine. We fur-
ther assumed that all oncogenic types are equally likely to be co-infected with other oncogenic
types, and decreased all type-specific HPV-positivity rates with the same percentage (6.6%) to
account for multiple infections.
In the absence of herd immunity, unvaccinated women were assumed to have the cervical
cancer risk as is currently observed in the Netherlands [42]. Full herd immunity was assumed
to be equally effective as vaccination in preventing both HPV-infections, CIN lesions and cervi-
cal cancer. When the herd immunity level was assumed to be e.g. 25%, then 25% of the infec-
tions, lesions and cancers that would have been prevented by vaccination, were averted in
unvaccinated women.
Table 1. Vaccination assumptions for base case analysis and sensitivity analyses.
Vaccine
type
Vaccine
duration†
Vaccine efﬁcacy
HPV-infections
without CIN
CIN
grade I
CIN
grade II
CIN grade
III
Cervical
cancer
Directly observed from PATRICIA
trial (base case)
Bivalent Lifelong 25.3% 35.0% 54.8% 93.2% 83.8%¥
Directly observed from FUTURE
trial
Quadrivalent Lifelong 21.4%‡ 29.7% 42.9% 45.5% 80.2%¥
Indirectly based on PATRICIA trial* Bivalent Lifelong 52.6% 34.4% 55.8% 62.5% 83.8%
Indirectly based on FUTURE trial* Quadrivalent Lifelong 42.6% 28.6% 50.6% 57.7% 80.2%
HPV = human papillomavirus; CIN = cervical intraepithelial neoplasia.
*Vaccine efﬁcacy is calculated by combining the reduction in type-speciﬁc HPV-infections observed in the trial, with the HPV-type distribution observed in
HPV-infections without cytological abnormalities (in the Netherlands) [43], and in CIN grade I, II, and III, and cervical cancer (in western Europe) [4].
†Trials do not (yet) show that vaccine efﬁcacy wanes; we assumed that if it would, vaccine boosters would be offered.
¥Because the follow-up of the trials is too short to give (meaningful) estimates for cervical cancer, we used the estimates from the indirect approach.
‡Observed vaccine efﬁcacy for high-risk HPV-infections combined with ASC-US (atypical squamous cells of undetermined signiﬁcance), trial results do
not include efﬁcacy for high-risk HPV-infections only.
doi:10.1371/journal.pone.0145548.t001
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Analyses and outcomes
For a pre-vaccination and a vaccinated cohort, we simulated the screening strategies described
earlier and determined their discounted costs and effects as compared to no screening. For
both cohorts, the optimal screening strategy was determined as follows. We first excluded all
dominated screening strategies, i.e. those strategies that were more costly and less effective
than (combinations of) other strategies. We then ranked the efficient strategies based on the
number of quality-adjusted life years (QALYs) gained and calculated their incremental cost-
effectiveness ratio (ICER), i.e. the additional costs per additional QALY gained compared to
the next less effective, efficient strategy. For each cohort, the optimal screening strategy was
then defined as the strategy with an ICER just below the willingness-to-pay threshold of
€50,000 per QALY gained, which is a commonly used threshold in cost-effectiveness analyses
for cervical cancer screening [29, 44].
The two optimal screening strategies were applied to unvaccinated women assuming herd
immunity levels of 0%, 25%, 50%, 75% and 100%. For all these levels, the ICER of screening
optimized to the pre-vaccination cohort as compared to screening optimized to the vaccinated
cohort was calculated. If the ICER reached above €50,000 per QALY gained, screening opti-
mized to the pre-vaccination risk level was no longer considered cost-effective for unvaccinated
women.
Sensitivity analyses
In the sensitivity analyses, we varied the following parameters.
Vaccine efficacy.
1. First, we used the vaccine efficacy from two randomized efficacy trials in which the quadri-
valent vaccine was used (FUTURE I [45] and FUTURE II [46]). The efficacy found in these
trials was lower than for the bivalent vaccine, i.e. 29.7%, 42.9% and 45.5% for CIN grade I, II
and III lesions, respectively [47]. Because in these trials HPV testing was only used when
cytological abnormalities were observed, the reduction in HPV-infections in women with-
out cytological abnormalities is not known. Instead, we used the reduction in HPV-positive
women with ASCUS, which was 21.4% [47]. Again, the efficacy for cervical cancer was esti-
mated using the type-specific reduction in HPV prevalence [41, 48] and the HPV-type dis-
tribution in cervical cancer [4], which resulted in an estimate of 80.2%.
2. Second, we estimated the efficacy for all disease stages by using the type-specific reduction
in HPV prevalence observed in the PATRICIA trial and the HPV-type distribution observed
in the Netherlands (for HPV-infections without cytological abnormalities) [43] and in west-
ern Europe (for CIN lesions and cervical cancer) [4]. This resulted in an assumed vaccine
efficacy of 52.6% for HPV-infections, and of 34.4%, 55.8% and 62.5% for CIN grade I, II
and III respectively. For cervical cancer, the efficacy remained at its base case value of
83.8%.
3. Finally, this indirect approach of combining the type-specific reduction in HPV prevalence
with the HPV-type distribution in HPV-infections, CIN lesions and cervical cancer was also
used to determine the vaccine efficacy for the quadrivalent vaccine. The assumed vaccine
efficacy was 42.6% for HPV-infections, 28.6%, 50.6%, 57.7% for CIN grade I, II and III
respectively and 80.2% for cervical cancer.
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Background risk for cervical cancer in unvaccinated women. Instead of assuming an
equal background risk for vaccinated and unvaccinated women, we included two sensitivity
analyses in which the background risk in unvaccinated women was assumed 50% higher and
50% lower than in vaccinated women.
Results
Base case analysis
For a pre-vaccination cohort, 6-yearly primary HPV screening in the age range 30–72 years is
most cost-effective (S3 Table). This corresponds to 8 screens in a lifetime. The optimal strategy
for vaccinated women is also primary HPV screening, but in a smaller age range (35–59 years)
and with a longer interval (every 12 years), corresponding with 3 lifetime screens (S4 Table).
Health effects. As compared to screening 3 times, screening 8 times reduces cervical can-
cer deaths with 161 per 100,000 unvaccinated women in the absence of herd immunity, and
with 28 in case of full herd immunity (Table 2). It thereby yields 388 and 34 more QALYs
gained when assuming 0% and 100% herd immunity, respectively (Table 3). However, it also
requires more screen tests, more referrals for colposcopy and more CIN treatments. For one
additionally prevented death, the required additional number of referrals for colposcopy
increased from 34 for 0% herd immunity to 118 for 100%.
Costs and cost-effectiveness. Screening 8 times instead of 3 increases total costs with
approximately €10.9 and €11.1 million assuming no and full herd immunity, respectively. Con-
sequently, the ICER of screening 8 times instead of 3 increased from €28,085 per QALY gained
in the absence of herd immunity to €35,042, €47,530, €77,541, and €322,234 for 25%, 50%,
75% and 100% herd immunity, respectively. From Fig 1, the estimated herd immunity level for
which screening 8 times would cost approximately €50,000 per QALY gained when compared
to screening 3 times, is 52%.
Sensitivity analyses
When vaccine efficacy was calculated indirectly from the FUTURE trial, the optimal screening
strategy for vaccinated women involved an additional screening round at age 71 (S5 Table). In
Table 2. Undiscounted health effects for unvaccinated women of primary HPV screening at ages 30–72 every 6 years (optimal for unvaccinated
women without herd immunity) and at ages 35–65 every 15 years (optimal for vaccinated women), as compared to no screening. For different levels
of herd immunity, results are given per 100,000 unvaccinated women.
Herd
immunity
level
Screening
strategy
# Primary
screens
# Triage
screens
# Referrals for
colposcopy
# False-positive
referrals (no CIN)
# CIN
grade I
# CIN
grade II
# CIN
grade III
# Cases
prevented
# Deaths
prevented
0% 30–72, 6y 717,049 55,427 10,188 873 3,805 2,360 3,029 1,416 589
35–59, 12y 277,073 20,127 4,718 271 1,479 1,014 1,782 982 423
25% 30–72, 6y 716,804 51,324 8,969 823 3,630 2,080 2,340 1,123 471
35–59, 12y 277,153 18,450 4,085 257 1,421 889 1,383 776 338
50% 30–72, 6y 716,579 47,130 7,756 770 3,468 1,802 1,648 832 348
35–59, 12y 277,233 16,752 3,447 242 1,357 765 985 579 248
75% 30–72, 6y 716,354 42,929 6,535 723 3,286 1,528 953 537 225
35–59, 12y 277,308 15,054 2,803 229 1,290 632 589 372 161
100%* 30–72, 6y 716,113 38,739 5,472 678 3,121 1,254 252 230 98
35–59, 12y 277,386 13,352 2,156 213 1,228 511 176 158 70
CIN = cervical intraepithelial neoplasia.
*We assume that with full herd immunity, unvaccinated women have the same cervical cancer risk as vaccinated women.
doi:10.1371/journal.pone.0145548.t002
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all other sensitivity analyses, the optimal strategy for vaccinated women was unchanged (S6
and S7 Tables).
Similar to the base case analysis, the ICER of using the strategy optimized to the pre-vacci-
nation cohort instead of to the vaccinated cohort, increased with increasing level of herd
immunity (Table 4). In sensitivity analyses with different efficacy assumptions, screening opti-
mized to the pre-vaccination population can be considered cost-effective as long as the herd
immunity level is below 50%-52%. When unvaccinated women would have a 50% lower
Table 3. Base case costs and QALYs gained as compared to no screening (both 3% discounted) of screening optimized to a pre-vaccinated cohort
and of screening optimized to a vaccinated cohort, and incremental cost-effectiveness of the former strategy as compared to the latter. For differ-
ent levels of herd immunity, results are given per 100,000 unvaccinated women.
Herd immunity level Screening strategy Costs Incremental costs QALYs gained Incremental QALYs ICER
Age range Interval No. of screens
0% 35–59 12y 3 €5,926,814 1,488
30–72 6y 8 €16,825,096 +€10,898,282 1,876 +388 €28,085
25% 35–59 12y 3 €5,136,318 1,184
30–72 6y 8 €16,064,406 +€10,928,088 1,495 +312 €35,042
50% 35–59 12y 3 €4,336,530 868
30–72 6y 8 €15,310,889 +€10,974,359 1,098 +231 €47,530
75% 35–59 12y 3 €3,539,526 556
30–72 6y 8 €14,556,455 +€11,016,928 698 +142 €77,541
100%* 35–59 12y 3 €2,720,635 231
30–72 6y 8 €13,816,140 +€11,095,505 265 +34 €322,234
QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio
*We assume that with full herd immunity, unvaccinated women have the same cervical cancer risk as vaccinated women.
doi:10.1371/journal.pone.0145548.t003
Fig 1. Incremental cost-effectiveness ratio (ICER) of screening optimized to a pre-vaccination cohort
as compared to screening optimized to a vaccinated cohort, for unvaccinated womenwho benefit
from different herd immunity levels, under both base case assumptions and sensitivity analyses.
doi:10.1371/journal.pone.0145548.g001
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background risk for cervical cancer, screening can be optimized to vaccinated women, regard-
less of the herd immunity level. If instead, unvaccinated women have a 50% higher background
risk, screening optimized to the pre-vaccination population should be continued until the herd
immunity reaches above ~68%.
Discussion
For both a pre-vaccination and a vaccinated cohort, primary HPV screening is more cost-effec-
tive than primary cytology or co-testing. The optimal number of lifetime screens varied from 8
for the pre-vaccination cohort, to only 3 for the vaccinated cohort. For unvaccinated women,
the adverse effects and costs of screening become more important as the herd immunity level
increases. Offering these women 8 instead of 3 lifetime screens incrementally required 34
colposcopy referrals per prevented death for 0% herd immunity, which increased to 118 refer-
rals for 100% herd immunity. The ICER of screening 8 times instead of 3 increased from
€28,085 per QALY gained in the absence of herd immunity to €322,234 at full herd immunity.
Screening optimized to the risk level in vaccinated women becomes more cost-effective than
screening optimized to the pre-vaccination risk level when the herd immunity reaches above
50%-55%.
To foresee whether and when the herd immunity will reach this level, countries need to
monitor the HPV-16/18 prevalence in unvaccinated women, starting with a reliable pre-vacci-
nation baseline measurement. A recent cross-sectional study among women aged 18–24 years
in Australia, in whom vaccination coverage was 55%-74% for 1–3 doses [49], showed a reduc-
tion in HPV-16/18 prevalence of 93% and 35% in vaccinated and unvaccinated women, respec-
tively, compared to the pre-vaccination prevalence [50]. From these early data, the estimated
herd immunity level would equal (0.35 / 0.93) 38%.
We have not incorporated vaccination coverage as a separate parameter in our analyses, the
reason for which is as follows. Vaccination coverage plays a role in two ways: first, it determines
how many unvaccinated women there are (which is important when evaluating how to screen
them), and second, it is one of the main determinants of herd immunity. Mathematical models
have been created to estimate the level of herd immunity given vaccination coverage [51–53].
Table 4. Results sensitivity analyses: Incremental cost-effectiveness ratio of screening optimized to a pre-vaccination cohort, as compared to
screening optimized to a vaccinated cohort.
Herd immunity
level
Vaccine efﬁcacy* Background risk in
unvaccinated women
Directly observed from FUTURE
trial
Indirectly based on PATRICIA
trial
Indirectly based on FUTURE
trial
+50% -50%
0% €28,085 €28,085 €31,450 €17,828 €80,972
25% €35,050 €34,675 €38,631 €22,950 €114,122
50% €46,471 €48,097 €49,747 €31,998 €175,596
75% €77,153 €78,139 €80,122 €56,390 €301,129
100%† €195,881 €303,352 €191,000 €157,043 QALYs
lost‡
QALYs = quality-adjusted life years.
*For vaccine efﬁcacy assumptions, see Table 1.
†We assume that with full herd immunity, unvaccinated women have the same cervical cancer risk as vaccinated women.
‡For unvaccinated women at 50% reduced cervical cancer risk, QALYs were lost when screening was optimized to the pre-vaccination risk level instead
of to the risk level in vaccinated women.
doi:10.1371/journal.pone.0145548.t004
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These models have been helpful in decision analyses concerning vaccination (also in boys), by
estimating its indirect effect in the unvaccinated. However, when it comes to screening deci-
sions that depend on current or near future herd immunity, it seems more appropriate to seek
guidance from actual measurements (of HPV prevalence in the unvaccinated) than from
model based predictions of herd immunity levels. Indeed, the exact relation between coverage
and herd immunity will only become established based on such measurements.
The manuscript primarily focused on the effect of decreasing the screening frequency of
uniform screening for unvaccinated women. For vaccinated women, this adjustment would be
cost-effective by definition. Meanwhile, it is important to point out that the harms of screening
the vaccinated 8 times instead of 3 were smaller than the life years gained (Table 3), meaning
that unadjusted screening did not result in a net loss in health for vaccinated women.
We optimized the screening strategy to the pre-vaccination risk level and to the risk level in
vaccinated women. For partly vaccinated cohorts, it could be beneficial to have a screening
strategy that is a compromise of these two strategies. In fact, when ignoring the costs and
efforts related to restructuring screening guidelines, it would likely be cost-effective to reduce
the screening frequency gradually while the herd immunity level increases. Adjusting national
screening guidelines every few years is not a very workable solution though. Likewise, it could
be cost-effective to tailor screening to vaccination status. Our results have shown that as soon
as the herd immunity level reaches 50%, then it is beneficial (in terms of cost-effectiveness) for
unvaccinated women to replace screening optimized to the pre-vaccination risk level with
screening optimized to the risk level in vaccinated women. If this already happens within a few
years, then establishing tailored screening by e.g. developing a vaccination registry that is
linked to the screening invitational system, may not be worthwhile. The (lack of) accumulation
of herd immunity over time is crucial in deciding whether the establishment of tailored screen-
ing would be worth these additional efforts. We performed our analyses under the assumption
that it is most realistic that countries will continue screening all women uniformly, and that a
once-only adjustment is made as soon as this seems justified for unvaccinated women.
Notable limitations are the following. First, we assumed that the efficacy of the vaccine has a
lifelong duration. Although until now, HPV vaccination trials have shown a sustained efficacy
[2, 3], it is possible that the efficacy will wane in the future. If the protection would fade away
and offering vaccination boosters would not be an option, then screening optimized to vacci-
nated women would probably be more intensive than in the current analyses, and unvaccinated
women could be screened accordingly from a lower herd immunity level onwards. Second, as
the follow-up of the vaccination trials is too limited to give (meaningful) estimates of the vac-
cine efficacy for cervical cancer, we had to estimate this efficacy indirectly. The decrease in CIN
grade III lesions does indicate that the vaccine is likely to prevent clinically relevant lesions,
and therefore also cancer [2, 47]. If the decrease in cervical cancer risk would be smaller than
estimated, vaccinated women would also require more intensive screening, again meaning that
unvaccinated women could be screened accordingly from a lower herd immunity level. Third,
we assumed an equal background risk for vaccinated and unvaccinated women. Because rea-
sons for refusing vaccination may vary widely (e.g. lack of knowledge about HPV, low per-
ceived risk of infection, concerns about safety, religious values) [54], the background risk in
unvaccinated women could both be higher or lower as compared to vaccinated women. In the
sensitivity analyses we showed that even if the background risk in unvaccinated women would
be 50% higher, then unvaccinated women could already be screened as vaccinated women
from ~68% herd immunity onwards. Finally, we have not modeled the effects of the nonavalent
vaccine, because its use is still limited compared to the bivalent and quadrivalent vaccine. If
vaccination with this more potent vaccine would lead to a less intensive optimal screening
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strategy for vaccinated women, the herd immunity level at which unvaccinated women could
be screened accordingly would be higher.
To our knowledge, this is the first study evaluating at what herd immunity level a once-only
uniform (equal for vaccinated and unvaccinated women) screening adaptation becomes, con-
sidering risks, benefits and costs, an option. Because vaccinated women are approaching the
age at which cervical cancer screening starts, the results of this study will be relevant in the near
future. It shows, that as long as stepwise adjustment or dichotomized screening based on vacci-
nation status are considered unfeasible, one may wait until the HPV-16/18 prevalence amongst
unvaccinated women drops below 50% of the pre-vaccination level, before considering adjust-
ing screening. Meanwhile, also the necessary evidence for a decrease in cervical cancer risk in
vaccinated women should become available.
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